RAD51 and Miyoshi myopathy: This study demonstrates that RAD51 is essential for “normal levels” of MM-cell resistance to DOX treatment, so that direct inhibition of RAD51 could be an effective addition to clinical regimens, enhancing the efficacy of genotoxic chemotherapies.